ArticleCureus2026
Anti-CGRP Monoclonal Antibodies in Chronic Migraine: A Position Statement of the Brazilian Academy of Headache and Orofacial Pain.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic migraine (CM) is a disabling neurological condition with high burden, common comorbidities, and a frequent profile of treatment resistance. Although there is progress in mechanism-based therapeutic approaches, such as anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), real-world data on their clinical use and positioning in Latin America remain limited. Methods A cross-sectional, expert-opinion survey of 21 Brazilian headache specialists was carried out to inform a position statement of the Brazilian Academy of Headache and Orofacial Pain. The electronic survey consisted of 49 structured questions that addressed clinical experience with CM, the prevalence of comorbid medication-overuse headache (MOH), the use of anti-CGRP mAbs fremanezumab and galcanezumab as treatment options, comparative assessment, therapeutic positioning, and consensus statements. Descriptive statistics were employed, and consensus was considered as 80% agreement. Results Twenty-one specialists participated; 14 (66.7%) had >20 years' experience. Misdiagnosis was common (16 (81.0%)), and 12 (57.1%) had a diagnostic delay of one year or more. The rate of treatment resistance was high (13 (61.9%) reported that over half of patients were non-responders to two or more prior preventives), and the prevalence of MOH was also high (17 (81.0%) estimated 80% coexistence or higher). The anti-CGRP mAbs were the most used therapies (fremanezumab 17 (81.0%), galcanezumab 18 (85.7%)) and were perceived by respondents as effective in reducing migraine days and improving quality of life. Safety and tolerability ratings reported by clinicians were favorable, with the most common reactions being injection-site reactions. Most clinicians did not indicate notable differences among agents, although no statistical comparison was performed. Early use was prescribed in CM with MOH sufferers (17 (85.0%)). The primary barrier was cost (19 (90.5%)), followed by a strong agreement with earlier use and region-specific guidance. Conclusions Diagnostic delays, high treatment resistance, and significant comorbidity burden characterize CM management in Brazil. In the opinion of the surveyed specialists, anti-CGRP mAbs are perceived as effective and well tolerated, particularly in patients with MOH, and most respondents favored their earlier positioning in the treatment algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.